Literature DB >> 35855194

Mucormycosis of the Breast in a Patient With Breast Carcinoma After COVID-19 Pneumonia.

S P Somashekhar1, Richa Jaiswal1, Rohit Kumar1, B C Ashok2, Susmita Rakshit3, Amit Rauthan4, H K Karthik1, Archa Prasad1, Herra Islam1, Aaron Fernandes1, Elroy Saldahana1, K R Ashwin1.   

Abstract

Mucormycosis is a rare, but potentially fatal, fungal infection which is caused by mucormyctes. These forms of fungi are typically known to infect immuno-compromised individuals but are rare in immunocompetent individuals. Herein, we report the case of a 52 year-old female who was diagnosed with right breast carcinoma in Manipal Hospital, a tertiary cancer care center. The patient was a known diabetic and hypertensive and who had recently recovered from coronavirus disease-2019 (COVID-19) pneumonia. In the due course of management, she developed mucormycosis infection at the operative site in her right breast where she had a radiation therapy-induced wound. This patient was successfully treated with an aggressive regimen of early surgical debridement along with administration of systemic amphotericin B. ©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.

Entities:  

Keywords:  Axillary dissection; COVID-19; breast carcinoma; chemotherapy; mucormycosis; neoadjuvant chemotherapy

Year:  2022        PMID: 35855194      PMCID: PMC9255654          DOI: 10.4274/ejbh.galenos.2022.2022-2-4

Source DB:  PubMed          Journal:  Eur J Breast Health


  9 in total

Review 1.  Mucormycoses.

Authors:  J Eucker; O Sezer; B Graf; K Possinger
Journal:  Mycoses       Date:  2001       Impact factor: 4.377

2.  Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum.

Authors:  G R GALE; A M WELCH
Journal:  Am J Med Sci       Date:  1961-05       Impact factor: 2.378

3.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

4.  Notes from the Field: COVID-19-Associated Mucormycosis - Arkansas, July-September 2021.

Authors:  Theresa M Dulski; Megan DeLong; Kelley Garner; Naveen Patil; Michael J Cima; Laura Rothfeldt; Trent Gulley; Austin Porter; Keyur S Vyas; Hazel K Liverett; Mitsuru Toda; Jeremy A W Gold; Atul Kothari
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-12-17       Impact factor: 17.586

5.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Shashank R Joshi; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-21

6.  Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections.

Authors:  Christine J Kubin; Thomas H McConville; Donald Dietz; Jason Zucker; Michael May; Brian Nelson; Elizabeth Istorico; Logan Bartram; Jennifer Small-Saunders; Magdalena E Sobieszczyk; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Open Forum Infect Dis       Date:  2021-05-05       Impact factor: 3.835

7.  Mucormycosis: An opportunistic pathogen during COVID-19.

Authors:  Iyer Mahalaxmi; Kaavya Jayaramayya; Dhivya Venkatesan; Mohana Devi Subramaniam; Kaviyarasi Renu; Padmavathi Vijayakumar; Arul Narayanasamy; Abilash Valsala Gopalakrishnan; Nachimuthu Senthil Kumar; Palanisamy Sivaprakash; Krothapalli R S Sambasiva Rao; Balachandar Vellingiri
Journal:  Environ Res       Date:  2021-07-06       Impact factor: 6.498

Review 8.  Epidemiology and Diagnosis of Mucormycosis: An Update.

Authors:  Anna Skiada; Ioannis Pavleas; Maria Drogari-Apiranthitou
Journal:  J Fungi (Basel)       Date:  2020-11-02

Review 9.  Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.

Authors:  Ge Song; Guanzhao Liang; Weida Liu
Journal:  Mycopathologia       Date:  2020-07-31       Impact factor: 3.785

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.